These studies provide insights into potential immune‐independent effects of existing BC immunotherapies targeting PD‐L1, or that pharmacologic or genetic PD‐L1 depletion could improve treatment responses to specific agents and suggest treatment response biomarkers. The gene discussed is CD274; the disease is breast cancer.